Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. (Q43217994)

16 November 2017

Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. (English)

1 reference

16 November 2017

1 reference

lymphoblastic leukemia

1 reference

W A Kamps

1

1 reference

16 November 2017

K M van der Pal-de Bruin

2

1 reference

16 November 2017

A J P Veerman

3

1 reference

16 November 2017

M Fiocco

4

1 reference

16 November 2017

M Bierings

5

1 reference

16 November 2017

R Pieters

6

1 reference

16 November 2017

17 December 2009

1 reference

16 November 2017

1 reference

16 November 2017

24

1 reference

16 November 2017

309-319

1 reference

16 November 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.258

16 November 2017

0 references

cites work

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Tutorial in biostatistics: competing risks and multi-state models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

7 January 2021

Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

7 January 2021

High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

7 January 2021

Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

7 January 2021

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

7 January 2021

Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.258

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.258

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference